zip >>> 19803
sector >>> Healthcare
fullTimeEmployees >>> 1456
longBusinessSummary >>> Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
city >>> Wilmington
phone >>> 302 498 6700
state >>> DE
country >>> United States
companyOfficers >>> []
website >>> http://www.incyte.com
maxAge >>> 1
address1 >>> 1801 Augustine Cut-Off
industry >>> Biotechnology
previousClose >>> 85.07
regularMarketOpen >>> 84.68
twoHundredDayAverage >>> 93.69561
trailingAnnualDividendYield >>> None
payoutRatio >>> 0
volume24Hr >>> None
regularMarketDayHigh >>> 87.34
navPrice >>> None
averageDailyVolume10Day >>> 1495785
totalAssets >>> None
regularMarketPreviousClose >>> 85.07
fiftyDayAverage >>> 92.06353
trailingAnnualDividendRate >>> None
open >>> 84.68
toCurrency >>> None
averageVolume10days >>> 1495785
expireDate >>> None
yield >>> None
algorithm >>> None
dividendRate >>> None
exDividendDate >>> None
beta >>> 1.064102
circulatingSupply >>> None
startDate >>> None
regularMarketDayLow >>> 84.06
priceHint >>> 2
currency >>> USD
regularMarketVolume >>> 1331261
lastMarket >>> None
maxSupply >>> None
openInterest >>> None
marketCap >>> 18928400384
volumeAllCurrencies >>> None
strikePrice >>> None
averageVolume >>> 1184817
priceToSalesTrailing12Months >>> 7.9280596
dayLow >>> 84.06
ask >>> 86.48
ytdReturn >>> None
askSize >>> 1200
volume >>> 1331261
fiftyTwoWeekHigh >>> 110.37
forwardPE >>> 22.776318
fromCurrency >>> None
fiveYearAvgDividendYield >>> None
fiftyTwoWeekLow >>> 62.48
bid >>> 86.85
tradeable >>> False
dividendYield >>> None
bidSize >>> 800
dayHigh >>> 87.34
exchange >>> NMS
shortName >>> Incyte Corporation
longName >>> Incyte Corporation
exchangeTimezoneName >>> America/New_York
exchangeTimezoneShortName >>> EDT
isEsgPopulated >>> False
gmtOffSetMilliseconds >>> -14400000
quoteType >>> EQUITY
symbol >>> INCY
messageBoardId >>> finmb_332954
market >>> us_market
annualHoldingsTurnover >>> None
enterpriseToRevenue >>> 7.294
beta3Year >>> None
profitMargins >>> -0.08003
enterpriseToEbitda >>> -132.035
52WeekChange >>> 0.16597056
morningStarRiskRating >>> None
forwardEps >>> 3.8
revenueQuarterlyGrowth >>> None
sharesOutstanding >>> 217372992
fundInceptionDate >>> None
annualReportExpenseRatio >>> None
bookValue >>> 10.752
sharesShort >>> 5281794
sharesPercentSharesOut >>> 0.0242
fundFamily >>> None
lastFiscalYearEnd >>> 1577750400
heldPercentInstitutions >>> 0.92403
netIncomeToCommon >>> -191068000
trailingEps >>> -0.889
lastDividendValue >>> None
SandP52WeekChange >>> 0.108078
priceToBook >>> 8.049665
heldPercentInsiders >>> 0.00656
nextFiscalYearEnd >>> 1640908800
mostRecentQuarter >>> 1593475200
shortRatio >>> 4.8
sharesShortPreviousMonthDate >>> 1596153600
floatShares >>> 184892580
enterpriseValue >>> 17414629376
threeYearAverageReturn >>> None
lastSplitDate >>> 967766400
lastSplitFactor >>> 2:1
legalType >>> None
morningStarOverallRating >>> None
earningsQuarterlyGrowth >>> 1.756
dateShortInterest >>> 1598832000
pegRatio >>> -44.27
lastCapGain >>> None
shortPercentOfFloat >>> 0.028499998
sharesShortPriorMonth >>> 4862319
category >>> None
fiveYearAverageReturn >>> None
regularMarketPrice >>> 84.68
logo_url >>> https://logo.clearbit.com/incyte.com
